Genetics can provide a systematic approach to discovering the tissues and cell types relevant for a complex disease or trait. Identifying these tissues and cell types is critical for following up on non-coding allelic function, developing ex-vivo models, and identifying therapeutic targets. Here, we analyze gene expression data from several sources, including the GTEx and PsychENCODE consortia, together with genome-wide association study (GWAS) summary statistics for 48 diseases and traits with an average sample size of 86,850, to identify disease-relevant tissues and cell types. We develop and apply an approach that uses stratified LD score regression to test whether disease heritability is enriched in regions surrounding genes with the highest specific expression in a given tissue. We detect tissue-specific enrichments at FDR < 5% for 30 diseases and traits across a broad range of tissues that recapitulate known biology. In our analysis of traits with observed central nervous system enrichment, we detect an enrichment of neurons over other brain cell types for several brain-related traits, enrichment of inhibitory neurons over excitatory neurons for bipolar disorder, and enrichments in the cortex for schizophrenia and in the striatum for migraine. In our analysis of traits with observed immunological enrichment, we identify enrichments of alpha beta T cells for asthma and eczema, B cells for primary biliary cirrhosis, and myeloid cells for lupus and Alzheimer's disease. Our results demonstrate that our polygenic approach is a powerful way to leverage gene expression data for interpreting GWAS signal.
INTRODUCTION
There are many diseases whose causal tissues or cell types are uncertain or unknown. Identifying these tissues and cell types is critical for developing systems to explore gene regulatory mechanisms that contribute to disease. In recent years, researchers have been gaining an increasingly clear picture of which parts of the genome are active in a range of tissues and cell types: for example, which parts of the genome are accessible, which enhancers are active, and which genes are expressed [1] [2] [3] . Combining this type of information with GWAS data offers the potential to identify causal tissues and cell types for disease.
Many different types of data characterizing tissue-and cell-type-specific activity have been analyzed together with GWAS data to identify disease-relevant tissues and cell types: histone marks [4] [5] [6] [7] , DNase I hypersensitivity (DHS) [8] [9] [10] [11] , eQTLs 3, 12 , and gene expression data [13] [14] [15] [16] . Of these data types, gene expression data (without genotypes or eQTLs) has the advantage of being available in the widest range of tissues and cell types. Therefore, methods for integrating gene expression data with GWAS data have the potential not only to identify system-level differences among traits-e.g., brain enrichment vs. immune enrichment-but also to obtain high resolution within a system-e.g., differentiating among brain regions or among immune cell types.
Indeed, previous work has shown that gene expression can be a useful source of information for identifying disease-relevant tissues and cell types from GWAS data. An initial application of the SNPsea algorithm 13, 14 analyzed a data set with gene expression in 249 immune cell types from mouse, together with genome-wide significant SNPs from GWAS of several immunological diseases, and reported disease-specific patterns of enrichment 13 . The DEPICT software 15 includes a method for joint analysis of GWAS summary statistics with a large gene expression data set 17 , and has been used to identify enriched tissues for height 18 and BMI 19 . In a recent study of migraine 16 , an analysis of genome-wide significant loci with expression data from the GTEx project identified cardiovascular and digestive/smooth muscle enrichments. These studies show that gene expression data are informative for disease-relevant tissues and cell types, and have led to biological insights about the diseases and traits studied. However, the methods applied in these studies restrict their analyses to subsets of SNPs that pass a significance threshold. To our knowledge, no previous study has modeled genome-wide polygenic signals to identify disease-relevant tissues and cell types from GWAS and gene expression data.
Here, we apply stratified LD score regression 6 , a method for partitioning heritability from GWAS summary statistics, to sets of specifically expressed genes to identify diseaserelevant tissues and cell types across 48 diseases and traits with an average GWAS sample size of 86,850. We first analyze two gene expression data sets 3, 15, 17 containing a wide range of tissues to infer system-level enrichments, recapitulating known biology. We also analyze chromatin data from the Roadmap Epigenomics project 2 across the same set of diseases and traits, and conclude that gene expression and chromatin provide complementary information. We then analyze gene expression data sets that allow us to achieve higher resolution within a system 3, [20] [21] [22] , identifying enriched brain regions, brain cell types, and immune cell types for several brain-and immune-related diseases and traits. Our results underscore that a heritability-based framework applied to gene expression data allows us to achieve high-resolution enrichments, even for very polygenic traits.
RESULTS

Overview of methods
We analyzed the five gene expression data sets listed in Table 1 , mapping mouse genes to orthologous human genes when necessary. To assess the enrichment of a focal tissue for a given trait, we follow the procedure described in Figure 1 . We begin with a matrix of normalized gene expression values across genes, with samples from multiple tissues including the focal tissue. For each gene, we compute a t-statistic for specific expression in the focal tissue (Online Methods). We rank all genes by their t-statistic, and define the 10% of genes with the highest t-statistic to be the gene set corresponding to the focal tissue; we call this the set of specifically expressed genes, but we note that this includes not only genes that are strictly specifically expressed (i.e. only expressed in the focal tissue), but also genes that are weakly specifically expressed (i.e. higher average expression in the focal tissue). For a few of the datasets analyzed, we modified our approach to constructing the set of specifically expressed genes to better take advantage of the data available (Online Methods). We add 100kb windows on either side of the transcribed region of each gene in the set of specifically expressed genes to construct a genome annotation corresponding to the focal tissue. (The choice of the parameters 10% and 100kb is discussed in Online Methods.) Finally, we apply stratified LD score regression 6 to GWAS summary statistics to evaluate the contribution of the focal genome annotation to trait heritability (Online Methods). We jointly model the annotation corresponding to the focal tissue, a genome annotation corresponding to all genes, and the 52 annotations in the "baseline model" 6 (including genic regions, enhancer regions, and conserved regions; see Table S1 ). A positive regression coefficient for the focal annotation in this regression represents a positive contribution of this annotation to trait heritability, conditional on the other annotations. We report regression coefficients, normalized by mean per-SNP heritability, together with a P-value to test whether the regression coefficient is significantly positive. Stratified LD score regression requires GWAS summary statistics for the trait of interest, together with an LD reference panel (e.g. 1000 Genomes 23 ), and has been shown to produce robust results with properly controlled type I error 6 . We have released open source software implementing our approach, and have also released all genome annotations derived from the publicly available gene expression data that we analyzed (see URLs). We call our approach LD score regression applied to specifically expressed genes (LDSC-SEG).
Analysis of 48 complex traits across multiple tissues
We first analyzed two gene expression data sets. The first data set, from the GTEx consortium v6p 3 , consists of RNA-seq data for 53 tissues, with an average of 161 samples per tissue (Table S2 , Online Methods). The second data set, which we call the Franke lab data set, is an aggregation of publicly available microarray gene expression data sets comprising 37,427 samples in human, mouse, and rat 15, 17 . After removing redundant data, this data set contained 152 tissues, including much better representation of immune tissues and cell types than the GTEx data set ( Table S3 , Online Methods). The gene expression values in the Franke lab data set already quantify relative expression for a tissue/cell-type rather than absolute expression for a single sample, and so we used these values in place of our t-statistics. For visualization purposes, we classified the 205 tissues and cell types in these data sets into nine categories; the classification is described in Table  S2 and Table S3 . The main goal of this multiple-tissue analysis was to identify system-level enrichments.
We analyzed GWAS summary statistics for 48 diseases and traits with an average sample size of 86,850 (Table S4) , applying LDSC-SEG for each of the 205 specifically expressed gene annotations in turn. The 48 traits included 12 traits from the UK Biobank 24 , 17 traits with publicly available GWAS summary statistics [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] , and 19 traits from the Brainstorm Consortium [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] . We excluded the HLA region from all analyses, due to its unusual genetic architecture and pattern of LD. For 30 of the 48 traits, at least one tissue was significant at FDR<5% (Figure 2 , Figure S1 and Table S5 ). Averaging across the most significant tissue for each of these 30 traits, the specifically expressed gene annotation spanned 17% of the genome and explained 38% of SNP-heritability ( Table S5 ). Several of our results recapitulate known biology: immunological traits exhibit immune cell-type enrichments, psychiatric traits exhibit strong brain enrichment, LDL and triglycerides exhibit liverspecific enrichments, BMI-adjusted waist-hip ratio exhibits adipose enrichment, and height exhibits enrichments in a variety of tissues in a pattern similar to previous analyses of this trait 18 . In addition, several of our results validate very recent findings from other genetic analyses: in particular, smoking status, years of education, BMI, and age at menarche show robust brain enrichments that recapitulate results from our previous analysis of genetic data together with chromatin data 6 . We also observe a cardiovascular enrichment for intracerebral hemorrhage, consistent with genetic evidence that this trait shares risk alleles with blood pressure levels 47 , and a brain enrichment for epilepsy, consistent with parallel unpublished work 48 .
In a data set with many tissues/cell types, related tissues will have highly overlapping gene sets. Because of this, and because we fit each tissue without adjusting for the other tissues analyzed, related tissues often appear enriched as a group. In this analysis, we are focused on identifying system-level enrichments, and so these correlated results do not limit interpretability. The following section similarly focuses on identifying system-level enrichments, while in later sections we focus on differentiating among related tissues/cell types within a system.
Comparison of expression-based approach to chromatin-based approach
We compared our approach to analyses of the same 48 diseases and traits using stratified LD score regression 6 in conjunction with chromatin data from the Roadmap Epigenomics project 2 (see URLs) instead of gene expression data. We constructed 397 cell-type-/tissuespecific annotations from narrow peaks in six chromatin marks-DNase hypersensitivity, H3K27ac, H3K4me3, H3K4me1, H3K9ac, and H3K36me3-each in a subset of 88 primary cell types/tissues. This analysis differed from our previous analysis of chromatin data 6 in that we used more recently available data on a larger set of chromatin marks, we consistently used narrow peaks as processed by Roadmap for all marks, and we controlled not only for the union of annotations for each mark, but also for the average of annotations for each mark (Online Methods).
We analyzed GWAS summary statistics for the 48 traits, applying stratified LD score regression to each of the 397 tissue-specific chromatin-based annotations in turn. For 43 of the 48 traits, at least one tissue was significant at FDR<5% ( Figure S2 and Table S6 ). Averaging across the most significant annotation for each of these 43 traits, the tissuespecific chromatin annotation spanned 2.8% of the genome and explained 41% of the SNPheritability (Table S6 ). Our results using chromatin data were generally concordant with the results of our gene expression analysis (Figure 3a) . However, in many instances the analysis of chromatin data detected more enrichments and/or enrichments at higher significance levels than the analysis of gene expression data. There are two potential explanations for this. First, the set of tissues and cell types for which data is available is different for the two analyses; while in general gene expression is available in a wider variety of tissues and cell types (particularly for within-system analyses; see below), in some instances the most significantly enriched tissue in the chromatin analysis was not available in the GTEx or Franke lab data sets. For example, fetal lung was highly significantly enriched for lung capacity (FEV1/FVC) in our analysis of chromatin data, but there was no data on fetal lung in the GTEx or Franke lab data sets. Second, the enrichments were generally much larger for the chromatin-based annotations than for the gene expression-based annotations that we analyzed. However, the gene expression-based annotations were larger (i.e. spanned more of the genome) than the chromatin-based annotations and were comprised of larger regions, reducing the amount of LD between SNPs in the annotation and SNPs not in the annotation; this explains why LDSC-SEG was well-powered to identify much smaller enrichments.
We observed notable differences between the enrichments identified by the two approaches for migraine (Figure 3b ). There is a long-standing scientific debate as to whether migraine has a primarily neurological or vascular basis 49 , and a previous analysis of the migraine GWAS data (not restricted to any subtype) together with the GTEx gene expression data reported both cardiovascular and digestive/smooth muscle enrichments 16 . Our analysis of gene expression data did not identify any significant enrichments for this migraine data set, and identified a cardiovascular enrichment but no significant digestive/smooth muscle enrichment for migraine without aura. On the other hand, our analysis with chromatin data identified a significant neurological enrichment as well as quantitatively smaller and less significant cardiovascular and digestive/smooth muscle enrichments for the migraine data set, but identified only a borderline significant enrichment in fibroblasts for migraine without aura (Figure 3b ). We hypothesize that this difference reflects a difference in power and in the cell types available in the two sources of data. For example, the top annotations for migraine in the chromatin analysis were neurospheres and fetal brain, neither of which was present in the gene expression data analyzed. Our results are consistent with the hypothesis that migraine without aura does indeed have a vascular component, and that another subtype of migraine may have a neurological basis which is sufficiently cell-type specific that the relevant cell types are not represented in either the GTEx or Franke lab data sets. Our results demonstrate that for a multiple-tissue analysis, chromatin and gene expression data are complementary sources of data, and that it is of interest to test both gene expression annotations and chromatin annotations for enrichment, since there are diseases such as migraine and migraine without aura for which only one of the two types of data yields a significant enrichment.
A major advantage of gene expression data is that it is available at finer tissue/cell-type resolution within several systems. In the within-system analyses that follow, we analyzed gene expression data from tissues/cell types for which we did not have comparable chromatin data to investigate more detailed patterns of tissue/cell-type specificity. Thus, these analyses could not have been conducted using chromatin data.
Analysis of 13 brain-related traits using fine-scale brain expression data
We identified 13 traits with CNS enrichment at FDR<5% in our gene expression and/or chromatin analyses: schizophrenia, bipolar disorder, Tourette syndrome, epilepsy, generalized epilepsy, ADHD, migraine, depressive symptoms, BMI, smoking status, years of education, neuroticism, and systolic blood pressure. The nervous system has been implicated, either with genetic evidence or non-genetic evidence, for each of these traits 6, 26, 37, 46, [48] [49] [50] [51] [52] , including systolic blood pressure, which is regulated in part via the autonomic nervous system 51 .
We first investigated whether some brain regions are enriched over other brain regions for these traits. While the multiple-tissue analysis included annotations for many different brain regions, the gene sets for the different brain regions were often highly overlapping so that for many traits, many brain regions were identified as enriched. For example, nearly every brain region in either the GTEx or Franke lab data was found to be enriched at FDR<5% (Figure 2 ) in schizophrenia. To differentiate among brain regions, we restricted ourselves to gene expression data only from samples from the brain in the GTEx data. We computed t-statistics within the brain-only data set; e.g. we computed t-statistics for cortex vs. other brain regions instead of cortex vs. other tissues in GTEx, and we used these new tstatistics to construct and test gene sets as in the multiple-tissue analysis. Individual-level data was not available for the Franke lab data set, and thus we could not compute withinbrain t-statistics for this data set.
An alternative approach would be to undertake a joint analysis of the original 13 annotations from the multiple-tissue analysis. However, joint analysis of 13 highly correlated annotations is likely to be underpowered, while re-computing t-statistics within the brain allows us to construct new annotations with lower correlations (Figure S3) , increasing our power. Moreover, differential expression within the brain may allow us to isolate signals from cell types or processes that are unique to a single brain region, separately from the cell types or processes that are unique to the brain but shared among brain regions. Thus, we use differential expression within the brain, rather than joint analysis of the original annotations, to differentiate among brain regions.
The results of our analysis comparing brain regions are displayed in Figure 4a , Figure S4a and Table S7a . We identified significant enrichments in the cortex relative to other brain regions at FDR<5% for bipolar disorder, schizophrenia, depressive symptoms, and BMI, and in the striatum for migraine. These enrichments are consistent with our understanding of the biology of these traits [53] [54] [55] [56] , but to our knowledge have not previously been reported in any integrative analysis using genetic data. We also identified enrichments in cerebellum for bipolar disorder, years of education, smoking status, and BMI. However, we caution that differential gene expression in samples from different brain regions can reflect the cell type composition of these brain regions as well as their function. In particular, the cerebellum is known to have a very high concentration of neurons 57 , and thus cerebellar enrichments could indicate either that the cerebellum is a region that is important in disease etiology, or that neurons are an important cell type.
To address the question of the relative importance of brain cell types, as opposed to brain regions, we analyzed the same set of traits using a publicly available data set of specifically expressed genes identified from different brain cell types purified from mouse forebrain 20 . The authors of this data set made lists of specifically expressed genes for each of the three brain cell types available, and these lists were all approximately the same size as the sets of specifically expressed genes in our previous analyses. We created annotations from these lists in the same way that we created annotations from the lists of top 10% expressed genes. The results of this analysis are displayed in Figure 4b , Figure S4b and Table S7b . We identified neuronal enrichments at FDR<5% for seven traits: bipolar disorder, schizophrenia, years of education, smoking status, BMI, neuroticism, and systolic blood pressure. The other cell types did not exhibit significant enrichment for any of the 13 brainrelated traits. The enrichment of neurons for all four of the traits with enrichment in cerebellum in the brain-region analysis supports the hypothesis that analyses of brain regions may be confounded by cell-type composition. The enrichment for systolic blood pressure is consistent with the role of autonomic regulation of this trait 51 .
To more precisely characterize the neuronal enrichments, we analyzed the seven traits with neuronal enrichment at FDR<5% using t-statistics computed by the PsychENCODE consortium 21 on differential expression in glutamatergic (excitatory) vs. GABAergic (inhibitory) neurons. The results are displayed in Figure 4c , Figure S4c and Table S7c ; we used Bonferroni correction in this analysis, as we were testing only 7x2=14 hypotheses. For bipolar disorder, genes that are specifically expressed in GABAergic neurons exhibited heritability enrichment, while genes specific to glutamatergic neurons did not. This result supports the theory that pathology in GABAergic neurons can contribute causally to risk for bipolar disorder 58, 59 .
Analysis of 22 immune-related traits using immune cell expression data
We identified 22 traits with immune enrichment at FDR<5% in our gene expression and/or chromatin analyses. This includes many immunological disorders: celiac disease, Crohn's disease, inflammatory bowel disease, lupus, primary biliary cirrhosis, rheumatoid arthritis, type 1 diabetes, ulcerative colitis, asthma, eczema, and multiple sclerosis. It also includes Alzheimer's and Parkinson's diseases, which are neurodegenerative diseases with an immune component previously identified from genetics 60, 61 , as well as several brainrelated traits---ADHD, anorexia nervosa, bipolar disorder, schizophrenia, Tourette syndrome, and neuroticism---and HDL, LDL, and BMI. Several of the brain-related traits have been previously suggested to have an immune component 46, 62, 63 , HDL and LDL have been linked to immune activation [64] [65] [66] , and obesity, in addition to contributing to inflammation 67 , can also be induced in mice through alterations of the immune system 68 . We investigated cell-type-specific enrichments for these traits in 292 immune cell types using gene expression data from the ImmGen project 22 , which contains microarray data on these cell types from mice. This data set contains data for many immune cell types that are not available in the multiple-tissue analysis, and because we compute t-statistics within the data set---i.e., each immune cell vs. all other immune cells---the gene sets are less overlapping than those of immune cell types in the multiple-tissue analysis.
We identified enrichments at FDR<5% for 13 traits. Results are displayed in Figure 5 , Figure S5 and Table S8 , and reveal highly trait-specific patterns of enrichment. For primary biliary cirrhosis, we identified an enrichment in B cells, consistent with literature on the importance of B cells for this trait 69, 70 . Lupus and Alzheimer's disease both exhibit enrichment in myeloid cells. The Alzheimer's disease result is consistent with existing literature on the importance of the innate immune system in Alzheimer's disease etiology 71 . Asthma and eczema both exhibited enrichment in alpha beta T cells. Several subclasses of alpha beta T cells have been shown to be important in asthma 72 ; to our knowledge, this result has not previously been reported in analyses of genetic data. Rheumatoid arthritis, Crohn's disease, inflammatory bowel disease, and multiple sclerosis all exhibited enrichments in a variety of cell types, consistent with complex etiologies for these diseases that involve many different immune cell types [73] [74] [75] . Schizophrenia and bipolar disorder both exhibited an enrichment in alpha beta T cells. Patients with bipolar disorder have been shown to have a reduction in types of alpha beta T cells, but have equal levels of B cells, NK cells, and monocytes compared to controls 76 . T cell levels have been shown to vary between schizophrenia cases and controls, but existing literature is not consistent in its description of the direction of effect 77 . Note that our analysis excludes the HLA region; a previous analysis of the HLA region for schizophrenia implicated the complement system through its role in synaptic pruning, a signal that is distinct from the signal we observe here 78 . Finally, we identified an enrichment in gamma delta T cells for BMI. While obesity is known to cause inflammation 67 , and gamma delta T cells are known to be involved in obesity-related inflammation 79 , gamma delta T cells have not to our knowledge been previously suggested to have a role in BMI etiology.
DISCUSSION
We have shown that applying stratified LD score regression to sets of specifically expressed genes identifies disease-relevant tissues and cell types. Our approach, LDSC-SEG, allows us to take advantage of the large amount of gene expression data available---including finegrained data for which we do not currently have a comparable chromatin counterpart---to ask questions ranging in resolution from whether a trait is brain-related to whether excitatory or inhibitory neurons are more important for disease etiology. We identified many significant enrichments that confirm or extend our current understanding of biology, including an enrichment of striatum for migraine, enrichment of GABAergic neurons for bipolar disorder, and an enrichment of myeloid cells for Alzheimer's disease. These results improve our understanding of these diseases, and highlight the power of GWAS as a source of biological insight.
There are several key differences between LDSC-SEG, which relies on gene expression data without genotypes or eQTLs, and approaches that require eQTL data 3, 12 . First, our approach can be applied to expression data sets such as the Franke lab data set, the Cahoy data set, the PsychENCODE data set, and the ImmGen data set that do not have genotypes or eQTLs available ( Table 1) . Second, to our knowledge, no method based on eQTLs has been shown to consistently identify system-level enrichments such as brain enrichments for psychiatric traits and immune enrichment for immunological traits, as we do here 3, 12 . Third, methods based on eQTLs require gene expression sample sizes that are large enough to detect eQTLs. In an analysis of data from the GTEx project, we determined that we could identify strong enrichments such as brain enrichment for schizophrenia with just one brain sample, though subtler enrichments had decreasing levels of significance as the gene expression data were down-sampled (Figure S6 , Online Methods). Results from our analysis of ImmGen data, which has 2.8 samples per cell type on average, confirm that LDSC-SEG can identify significant enrichments even when the gene expression data has a small number of samples per tissue/cell type, in contrast to eQTL-based methods.
Our polygenic approach also differs from other gene expression-based approaches such as SNPsea 13, 14 and DEPICT 15 , which restrict their analyses to subsets of SNPs that pass a significance threshold. For comparison purposes, we repeated the multiple-tissue analysis using SNPsea and DEPICT. We also repeated the multiple-tissue analysis by analyzing our annotations using MAGMA, a recently developed gene set enrichment method 80 instead of stratified LD score regression 6 . Results are displayed in Figures S7-S11 (see Online Methods). Many broad patterns were consistent across all approaches: immune enrichment for many immunological diseases, liver enrichment for lipid traits, adipose enrichment for BMI-adjusted waist-hip ratio, and enrichment in several tissues for height and heel T-score. However, there were also several discrepancies. First, SNPsea and DEPICT, the two approaches based on top SNPs, did not identify many of the CNS enrichments for brain-related traits identified by LDSC-SEG and by MAGMA. Second, DEPICT and MAGMA identified more enrichments than LDSC-SEG overall, including some enrichments with unclear relationships to known biology. We hypothesized that LDSC-SEG did not identify some of these enrichments because we jointly model our gene expressionbased annotations with the many potential genomic confounders that are included in the baseline model (e.g. exons). We conducted simulations that confirmed that LDSC-SEG is the only approach that is well-powered to identify true enrichments for polygenic traits while avoiding genomic confounding (Figure S12 ; see Online Methods).
Our work has several limitations. First, our approach is fundamentally limited by the availability of gene expression data; for example, if the tissue/cell type that is most relevant for a disease occurs in a stage of development that has not been assayed, then we cannot identify enrichments in that tissue/cell type. Second, when analyzing gene expression data from different tissues, cell type composition can confound the analysis, as we demonstrated in our comparison of brain regions. Third, tissues/cell types with similar gene expression profiles to a causal tissue/cell type will be identified as relevant to disease, just as SNPs in LD with a causal SNP will be identified as associated to disease in a GWAS; thus, significant tissues/cell types should be cautiously interpreted as the "best proxy" for the truly causal tissue/cell type, which may be unobserved. Finally, because our approach uses stratified LD score regression, it cannot be applied to custom array data, and it requires a sequenced reference panel that matches the population studied in the GWAS 6 .
Our power to identify disease-relevant tissues and cell types will improve as GWAS sample sizes continue to grow and gene expression data is generated in new tissues and cell types. This will help advance our understanding of disease biology and lay the groundwork for future experiments exploring specific variants and mechanisms.
URLs
• LDSC software, including LDSC-SEG: https://github.com/bulik/ldsc. • Gene sets and LD scores from this paper: https://data.broadinstitute.org/alkes group/LDSCORE/. 15, 17 Human/mouse/rat 152 tissues/cell types Array Cahoy 20 Mouse 3 brain cell types Array PsychENCODE 21 Human 2 neuronal cell types RNA-seq ImmGen 22 Mouse 292 immune cell types Array Table 1 : List of gene expression data sets used in this study. We analyzed five gene expression data sets: two (GTEx and Franke lab) containing a wide range of tissues and three (Cahoy, PsychENCODE, ImmGen) with more detailed information about a particular tissue.
Figure 1:
Overview of the approach. For each tissue in our gene expression data set, we compute t-statistics for differential expression for each gene. We then rank genes by tstatistic, take the top 10% of genes, and add a 100kb window to get a genome annotation. We use stratified LD score regression 6 to test whether this annotation is significantly enriched for per-SNP heritability, conditional on the baseline model 6 
Figure 2:
Results of multiple-tissue analysis for selected traits. Results for the remaining traits are displayed in Figure S1 . Each bar represents a tissue/cell type from either the GTEx data set or the Franke lab data set. The width of each bar is proportional to its height, for easier visualization. *: y-axis has been rescaled to fit the data. The dashed line represents the FDR<5% cutoff, -log10(P)=2. 86 . Numerical results are reported in Table S5 .
A.
B. Figure S5 . The width of each bar is proportional to its height, for easier visualization. The dashed line represents the FDR<5% cutoff, -log10(P)=3.08. Numerical results are reported in Table S8 .
ONLINE METHODS
Computing t-statistics. When computing the t-statistic of each gene for a focal tissue, we excluded all samples from the same tissue category (see "Tissue categories and covariates" below). For example, when computing the t-statistic of specific expression for each gene in cortex using GTEx data, we compared expression in cortex samples to expression in all other samples, excluding other brain regions. We chose to exclude other brain regions because we wanted to include genes that are more highly expressed in brain tissues than in non-brain tissues, even if they are not specific to cortex within the brain. This procedure results in a higher correlation among the t-statistics for the different brain regions; in a separate analysis, we compute within-brain t-statistics to disentangle this signal. Thus, for a focal tissue (e.g., cortex) in a larger tissue category (e.g., brain), we computed the t-statistic for gene g as follows. We first constructed a design matrix X where each row corresponds to a sample either in cortex or outside of the brain. The first column of X has a 1 for every cortex sample and a -1 for every non-brain sample. The remaining columns are an intercept and covariates (see "Tissue categories and covariates" below). The outcome Y in our model is expression. We fit this model via ordinary least squares, and compute a t-statistic for the first explanatory variable in the standard way:
where MSE is the mean squared error of the fitted model; i.e.,
where N is the number of rows in X. This gives us a t-statistic for each gene for the focal tissue. We then select the top 10% of genes, add a 100kb window around their transcribed regions, and apply stratified LD score regression to the resulting genome annotations as described below.
Modifications of our approach. For some analyses, we modified our approach to constructing sets of specifically expressed genes to better take advantage of the data available.
• Franke lab data set. The values in the publicly available matrix are not a quantification of expression intensity, but rather a quantification of differential expression relative to other tissues in this data set. Thus, it was not appropriate to compute t-statistics in this data set. We used the original values in place of our t-statistics, then proceeded as described in Figure 1 . • Cahoy data set. The data set of Cahoy et al. had available sets of specifically expressed genes for the three cell types that each had between 1,700 and 2,100 genes. We took these to be the gene sets for the three cell types, then proceeded as in the standard approach, adding a 100kb window and applying stratified LD score regression. • PsychENCODE data set. The PsychENCODE data set had available t-statistics for GABAergic neurons vs. Glutamatergic neurons. We used these t-statistics, rather than computing our own.
For the other data sets we analyzed (GTEx, GTEx brain regions, ImmGen), we used the approach described in Figure 1 . We view it as an advantage of our method that it can be flexibly adapted to many different types of data.
Tissue categories and covariates.
• For the multiple-tissue GTEx analysis, we used the "SMTS" variable ("Tissue Type, area from which the tissue sample was taken") to define the tissue categories (Table S2 ). We used age and sex as covariates. • For the analysis of GTEx brain regions, we set each tissue to be its own category, and we used age and sex as covariates. • For the ImmGen analysis, we defined tissue categories using the classification on the main page of immgen.org of cell types into categories: B cells, gamma delta T cells, alpha beta T cells, innate lymphocytes, myeloid cells, stromal cells, and stem cells ( Table S8) .
The classification at immgen.org also has a "T cell activation" category that we collapsed into the alpha beta T cell category because it had data on alpha beta T cells at different stages of activation. We did not have any covariates. • For the Franke lab data set, Cahoy data set, and PsychENCODE data set, we did not compute t-statistics and so we did not have tissue categories or covariates (see "Modifications of our approach" above).
Choice of parameters.
Our approach includes two parameters: the proportion of genes selected, which we set to 10%, and the window size around each gene, which we set to 100kb. To choose these two parameters, we ran the approach with six different parameter settings ({2%, 5%, 10% of genes} x {20kb, 100kb windows}) on two diseasesschizophrenia and rheumatoid arthritis-and two corresponding GTEx tissues-brain (all brain regions) and blood (LCLs and whole blood)-which are widely known to be diseaserelevant tissues. We determined that of the parameter settings we tested, 10% of genes and 100kb produced the most significant P-values for identifying brain enrichment for schizophrenia and blood enrichment for rheumatoid arthritis, so we used these parameters for the remaining analyses.
Application of stratified LD score regression. Stratified LD score regression 6 is a method for partitioning heritability. Given (potentially overlapping) genomic annotations ! , … , ! , one of which is the category of all SNPs, we model the causal effect of SNP j on phenotype Y as drawn from a distribution with mean 0 and variance
(If the genomic annotations are real-valued rather than subsets of SNPs, we can replace { ∈ ! } with any other function of the SNP indices 81 .) We then model the phenotype Y as depending linearly on genotype: = ⋅ + , where X is a vector of SNP values for an individual, and each SNP has been standardized to mean 0 and variance 1 in the population. Because each SNP is standardized, and because ! has mean zero, we can call ! the per-SNP heritability of SNP i. (Note that here, because we model as random, our definition of heritability is different from definitions of heritability in which is fixed, and so we are estimating a fundamentally different quantity than some other methods 82 .)
